Diadexus, Inc. announced revenue guidance for the first quarter ended March 31, 2016. Preliminary total revenues, comprised entirely of product sales, for the quarter ended March 31, 2016 were approximately $3.5 million, consistent with $3.5 million for the fourth quarter of 2015. Revenues reflect the loss of one of the Company's customers for the PLAC(r) ELISA Test, Atherotech, which filed for bankruptcy March 4, 2016, an increase in PLAC(r) ELISA Test volumes from other customers, and growth in PLAC(r) Activity Test volumes from new customers.

Diadexus' second FDA-cleared test PLAC(r) Activity was launched actively in the fourth quarter of 2015.